Dr. Robert Devenyi is Professor of Ophthalmology and Vision Sciences at the University of Toronto as well as the Ophthalmologist-in-Chief, Director of Retinal Services and Co-Director of the Donald K. Johnson Eye Institute at the University Health Network. He is the Retinal Surgery Lead at the Kensington Eye Institute. Dr. Devenyi is the Karen and William Barnett Chair Ophthalmology at the University in Toronto, and the Team Ophthalmologist for the Toronto Maple Hockey Club.
Dr. Devenyi specializes in all aspects of medical and surgical retinal disease, as well as combined cataract and retinal surgery. He is the only Retinal Surgeon in Canada to have successfully implanted the Argus II Artificial Retina. In addition to the Argus II retinal implant, his research interests include the development of a non-invasive choroidoscope to replace retinal angiography, the development of the world’s first bioengineered permanent vitreous substitute and the use of a pico-second laser for vitrectomy and cataract surgery.
Dr. Devenyi graduated summa cum lauda from the University of Toronto School of Medicine. He completed his Ophthalmology training at the University of Toronto and then did further training in vitreoretinal surgery at the Medical College of Wisconsin.
Dr. Samuel Markowitz is the Director of the Low Vision Rehabilitation Program at the University of Toronto, Department of Ophthalmology and Vision Science.
His active practice covers all aspects of low vision rehabilitation including pediatric low vision. His current research interests are aimed at elucidating various aspects of visual function and functional vision parameters. Under study are aspects related to preferred retinal loci and their relationship to scotomata and to the oculomotor functions associated with refixation precision and fixation stability.
Dr. Markowitz has presented his work at numerous and various professional meetings nationally and internationally, and in many peer reviewed scientific papers nationally and internationally. In 2017 he was awarded the Long Service Recognition Certificate from the Trillium Health Partners honoring 30 years of dedicated service to patients in Mississauga. In 2016 he was awarded the Lifetime Achievement Award from Eye Physicians and Surgeons of Ontario, Ontario Medical Association in recognition of a distinguished career of service to the specialty of Ophthalmology.
In 2009 he was awarded the Achievement Award from the American Academy of Ophthalmology for professional accomplishments in Low Vision Rehabilitation. In 2009 he was awarded the Recognition for outstanding service to the profession of ophthalmology – from the American Academy of Ophthalmology for the development and maintenance of the Preferred Practice Patterns guidelines. In 2006 he was awarded the Distinguished Service Award from the Low Vision Rehabilitation Section of the American Optometric Association for professional accomplishments in Low Vision Rehabilitation and presented to him at the annual meeting in Boston, Ma., USA. In 2006 he was awarded the Secretariat Award from the American Academy of Ophthalmology for service and leadership in development of scientific and continuous education programs in Low Vision Rehabilitation at the 2003-6 Annual Meetings.
Dr. Raymond Stein is the Medical Director of the Bochner Eye Institute and one of the most experienced and respected ophthalmologists in North America. He has been honored with numerous awards from prestigious international medical organizations including the ‘Honour Award’ from both the American Academy of Ophthalmology and the Contact Lens Association of America, along with the ‘Innovators Award’ from the American Society of Cataract and Refractive Surgery. Dr. Stein also served as president of the Canadian Society of Cataract and Refractive Surgery.
Dr. Raymond Stein has been invited to lecture at numerous universities and medical conferences. and has published various journal and magazine articles, book chapters and books. With more than 200,000 successful eye surgeries performed, Dr. Stein has established himself as an expert and pioneer in refractive and implant surgery. As a testament to his exceptional surgical talents, he was chosen to serve as the chief eye surgeon for the W Network’s Style by Jury. He also serves as the editor of the prominent scientific journal, Clinical and Surgical Ophthalmology.
Dr. Stein began his career by completing a medical degree at the University of Toronto Medical School. Continuing his education, Dr. Raymond Stein performed an ophthalmology residency at the world-renowned Mayo Clinic and a cornea and external diseases fellowship at the Wills Eye Hospital in Philadelphia. In addition to serving as the Medical Director at Bochner Eye Institute, Dr. Raymond Stein is the past Chief of Ophthalmology at the Scarborough Hospital in Toronto, is on the Board of Directors of the Foundation Fighting Blindness, and is the Cornea Consultant at the Mount Sinai Hospital. He also serves as an Associate Professor of Ophthalmology at the University of Toronto
Michael J Berry II has over 25 years of experience at the forefront of vision and retina research. Michael is an Associate Professor of Princeton University and the Princeton Neuroscience Institute. He was Co-Director of the Program in Neuroscience at Princeton University and Methods in Computational Neuroscience at the Marine Biological Laboratory in Woods Hole, MA. Michael is a recipient of the Pew Scholars in the Biomedical Sciences award and the McKnight Technology Award.
Prior to becoming CEO of Optimal Acuity Corporation, Michael served as its Chief Science Officer for four years.
He received his PhD in Physics from Harvard University and his BSc in Physics with a Minor in Philosophy from University of California, Berkeley. He was the National Squash Champion in 1994 and the New Jersey State Champion in 2001 and lives in Princeton, NJ.
Michael James Berry has been at the forefront of laser research for over 50 years and involved with bringing cutting edge laser medical devices to market for over 3 decades. He has successfully led the regulatory process for multiple ophthalmic medical devices to achieve approval from the FDA and other regulatory agencies.
Michael Berry is a physical chemist who has discovered chemical lasers and used lasers of all types for chemical, medical, and other applications. His current research interests include vision improvement for patients with age-related macular degeneration and for patients with age-related focus dysfunction (aka presbyopia).
Michael Berry discovered over 100 chemical lasers and used them to understand intimate details of chemical reaction dynamics, such as the distribution of reaction exoergicity into product electronic and vibrational states. He also invented vibrational overtone laser photochemistry, methods for laser isotope separation, photoacoustic Raman spectroscopy, methods and apparatus to correct ocular refractive errors and to improve vision for patients with age-related macular degeneration, methods and apparatus for skin rejuvenation and methods and apparatus for early stage lung cancer detection. He has published over 140 works (peer-reviewed papers, book chapters, etc.) in the scientific, medical, and patent literatures.
Michael Berry is currently the President of Antropix Corporation and the President of Optimal Acuity Corporation. He has previously been the Director of the Corneal Shaping Program at Sunrise Technologies, the Robert A. Welch Professor of Chemistry at Rice University, the Manager of the Photon Chemistry Department at Allied Chemical Corporation (now Honeywell International Inc.), and Assistant, then Associate, Professor of Chemistry at the University of Wisconsin in Madison. He has received a National Science Foundation Fellowship (1969), a Merck Faculty Award, a Camille and Henry Dreyfus Teacher-Scholar Award, an Alfred P. Sloan Fellowship, a John Simon Guggenheim Fellowship, the Phi Lambda Upsilon Fresenius Award, and the American Chemical Society Award in Pure Chemistry.
He is a Fellow of the American Association for the Advancement of Science. Michael received his Bachelor of Science in Chemistry from the University of Michigan in Ann Arbor, MI, and received his PhD in Physical Chemistry degree in 1970 from the University of California, Berkeley. He and his wife Patricia live in Austin, Tx.
Praveena Joseph de Saram has over 15 years of experience in research in Physics and Neuroscience and over 10 years of management experience in the start-up and not-for profit sectors.
Prior to joining OAC, Praveena was Managing Director of the RCCI, a not-for profit supporting people with disabilities and CEO of Poopooh LLC, an innovative triple bottom line pet product manufacturer. Previously, she was a management consultant with AT Kearney and a scientist with the Princeton Neuroscience Institute and Retrosense Therapeutics, a division of Allergan Plc.
Praveena serves on the Board of the Princeton-Blairstown Center and is the Chair of the Board of the Rehabilitation Centre for the Communication Impaired. She also served on the board of the Princeton University Store and the National Steering Committee of Princeton University’s Annual Giving Campaign.
Praveena received her masters in Physics from the University of Oxford and her masters in Molecular Biology and Neuroscience from Princeton University. She lives in Princeton, NJ with her husband, daughter and two dogs.
Steve Matthesen is Chief Strategy Officer at NielsenIQ, which he recently rejoined after assisting Advent International in the acquisition of Global Connect.
Most recently, Steve was the CEO of DTN, a data and analytics company that brings advanced analytics to new spaces including weather, Agriculture, and Energy. Prior to DTN, Steve was President and Chief Executive Officer of Acosta, the leading Sales and Marketing agency in North America. Before Acosta, Steve held several roles at Nielsen including President, Nielsen Latin America and President, Global Retail and Product Leadership. He is experienced commercially and strategically across 106 countries. Previously, Steve was a Partner and Managing Director at The Boston Consulting Group (BCG), leading the global Supply Chain practice and was active in BCG’s consumer packaged goods and retail industry practices.
Additionally, Steve served as an officer in the United States Air Force where he managed a team of over 200 engineers and scientists on numerous projects to deliver military and scientific satellites into space.
Gregg Tenser is co-portfolio manager for the Small and SMID Cap Value Strategies at Poplar Forest Capital. Before joining Poplar Forest Capital in 2019, Gregg spent 16 years at NWQ where he served as the Portfolio Manager of the NWQ Global All Cap Strategy, in addition to covering the Healthcare sector for the firm’s portfolios.
Previously in his career, Gregg spent two years at Sturdivant & Company, a value-oriented institutional money manager. Additionally, he held the position of Vice President and Senior Analyst at Federated Investors where he also served as Director of Equity Research, and he was a Senior Analyst at First Chicago Investment Management Company.
Gregg received his A.B. in Economics and Psychology from Duke University and his M.B.A. with high distinction from the University of Michigan. In addition, he earned the designation of Chartered Financial Analyst in 1999.
Steven McConnell has spent most of his career in Leasing, Project Finance and Real Estate. He has been an active angel investor and advisor, both personally and through his firm for most of his adult life. He began his leasing career at Sperry Credit Corporation in the 1970s and progressed to Chase Investment Bank as a Managing Director and Prudential Bache, where he was a Director and second in command of the structured finance division, which comprised leasing, real estate, and project finance. He has been active at the leading edge of structured transactions for the last two decades with Ridgewood Partners and most recently Knight, Tallman, and its joint venture with Wachovia Bank. Steve received his BS from the University of Pennsylvania’s Wharton School and his MBA from Harvard Business School.